CNBC March 16, 2024
Annika Kim Constantino

Key Points

– The blockbuster weight loss drug Wegovy is now approved in the U.S. for heart health.

– But some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.

– Plans are likely to take notice of Wegovy’s new approval and start considering whether to cover the treatment when they next update their formularies.

In the U.S., Wegovy is no longer just for weight loss.

The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. But that may not translate to wider...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Employer, Insurance, Patient / Consumer, Pharma / Biotech, Provider
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article